Characteristics of Hospitalized Children With SARS-CoV-2 in the New York City Metropolitan Area

Sourabh Verma, MD,a Rishi Lumba, MD,b Heda M. Dapul, MD,a,b Gabrielle Gold-von Simson, MD, MS,a Colin K. Phoon, MD, MPhil,a,b Jennifer L. Lighter, MD,a,b Jonathan S. Farkas, MD,a,b Alexandra Vinci, MD,c Asif Noor, MD,c Vanessa N. Raabe, MD,a,b David Rhee, MD, MS,c Mona Rigaud, MD,a Pradeep V. Mally, MD,a,b Tara M. Randis, MD, MS,a,b Benard Dreyer, MD,a,b Adam J. Ratner, MD, MPH,a b,c Catherine S. Manno, MD,a Arun Chopra, MDa,b

ABSTRACT

OBJECTIVES: To describe the characteristics of hospitalized children with severe acute respiratory syndrome coronavirus 2 in New York City metropolitan area.

PATIENTS AND METHODS: This was a multicenter, retrospective cohort study at 4 hospitals comprising 82 hospitalized children (0–21 years) who tested positive for severe acute respiratory syndrome coronavirus 2 after symptoms and risk screening between March 1 and May 10, 2020. We subdivided patients on the basis of their admission to acute or critical care units and by age groups. Further subanalyses were performed between patients requiring respiratory support or no respiratory support.

RESULTS: Twenty-three (28%) patients required critical care. Twenty-nine (35%) patients requiring respiratory support, with 9% needing mechanical ventilation, and 1 required extracorporeal support. All patients survived to discharge. Children with any comorbidity were more likely to require critical care (70% vs 37%, P = .008), with obesity as the most common risk factor for critical care (63% vs 28%, P = .02). Children with asthma were more likely to receive respiratory support (28% vs 8%, P = .02), with no difference in need for critical care (P = .26). Children admitted to critical care had higher rates of renal dysfunction at presentation (43% vs 10%, P = .002).

CONCLUSIONS: Children with comorbidities (obesity and asthma in particular) were at increased risk for critical care admission and/or need for respiratory support. Children with renal dysfunction at presentation were more likely to require critical care.
The coronavirus disease 2019 (COVID-19) pandemic has spread to >210 countries, with the highest number of infections and deaths reported in the United States. Although the number of new infections and deaths are declining in previous US hotspots, many other states are now reporting a concerning upsurge in the number of new infections. Children have had a relatively low rate of symptomatic infections and a less-serious course of infection, as reported to date. There is a recently described entity called multisystem inflammatory syndrome in children, which is associated with recent infection or exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), suggesting that children may also suffer from distinctive consequences of this infection.

There is still a paucity of published data among hospitalized children with SARS-CoV-2. The early published reports originating from China in which researchers describe the clinical spectrum of this infection in children have different results and risk factors from recent small case series from the United States. In addition, the final clinical outcome for many patients (up to one-third) had not yet been determined at the time of publication from majority of smaller case series from the United States. To this end, we studied the clinical characteristics, laboratory findings, and short-term outcomes among pediatric and adolescent inpatients testing positive for SARS-CoV-2 through hospital discharge.

**METHODS**

This was a multicenter, retrospective cohort study including patients aged 0–21 years who were admitted to any of the pediatric acute or critical care units during hospitalization at a large health care system and its academic affiliate, between March 1 and May 10, 2020. All patients were managed until discharge or end of the study period (June 10, 2020). The patients were admitted to acute or critical care units on the basis of individual unit admission guidelines at clinical teams’ discretion. The diagnosis of SARS-CoV-2 was made by real-time reverse transcriptase polymerase chain reaction of nasopharyngeal swabs of patients with any evolving symptoms of COVID-19 as described by the Centers for Disease Control and Prevention, such as fever, respiratory symptoms, fatigue, headache, gastrointestinal symptoms, and new loss of taste or smell and on risk assessment based on history. The testing was mostly uniform across all institutions due to being a part of the same health care system or university affiliation. Initially, testing samples were sent to New York City (NYC) Department of Health and Mental Hygiene for processing. By April 1, all participating hospitals were performing “in-house” testing after Food and Drug Administration granted Emergency Use Authorization of reverse transcriptase polymerase chain reaction test for SARS-CoV-2 (Roche Cobas SARS-CoV-2 Test and Cepheid Xpert Xpress SARS-CoV-2 Test). The local institutional review boards approved the study with a waiver of consent and relevant data user agreements. Seven of these patients were included in other case series publications.

Information collected included demographics, presenting symptoms, laboratory and imaging results, treatments, and clinical outcomes. Patients were subdivided and compared by highest level of care during admission (acute care versus critical care unit) and by age groups (<1, 1–5, 6–14, and 15–21 years). Further subanalyses of the data were performed comparing patients who received any respiratory support during hospitalization. BMI was calculated by using a BMI calculator from Centers for Disease Control and Prevention for age and sex, and subjects were categorized as obese if they were ≥95th percentile or BMI ≥30 and as overweight if they were 85th–95th percentile or BMI 25 to <30 for age ≥2 years. Because of the nature of the study, data collection for obtaining history was not standardized within the cohort, and all testing and management plans were undertaken at the clinical team’s discretion. Categorical variables were compared by using Pearson χ² test or Fisher exact test. Medians of continuous variables were compared by using the Mann–Whitney test, and means were compared by using Student t test. GraphPad Prism8 software was used for statistical analysis. A P value of <.05 was considered significant.

**RESULTS**

We identified 82 hospitalized children who tested positive for SARS-CoV-2. The majority were male (63%), and the median age was 5 years (interquartile range [IQR]: 2.5 months to 15.2 years) (Table 1). Among all patients, 23 (28%) were admitted to critical care units during hospitalization. One patient required venovenous extracorporeal membrane oxygenation (ECMO). At the end of the study period, all patients remained alive and were discharged from the hospital. The median duration from symptom onset to hospital admission was 1 day (IQR: 1–4 days) and length of stay was 3 days (IQR: 2–5 days). The majority of the patients were admitted because of respiratory distress, sepsis, evaluation, or severity of gastrointestinal symptoms.

**Demographics**

About half of all patients (49%) were Hispanic and Latino, 22% were non-Hispanic white, 9% were non-Hispanic African American, 5% were non-Hispanic Asian, and 15% were multiple, other, or unknown race. This was consistent with overall patient population at these 4 institutions. African American, Hispanic, and Asian patients together were represented more frequently among those requiring critical care versus acute care but this difference was not statistically significant (74% vs 59%, P = .22). Thirty-three patients (40%) were aged <1 year, 9 (11%) were aged 1 to 5 years, 19 (23%) were aged 6 to 14 years, and 21 (26%) were aged 15 to 21 years. Distribution of presenting symptoms and need for admission to critical care or acute care units among patients of all age groups is shown in Figs 1 and 2. Fourteen patients (67%) in the 15 to 21 years age group and 9 patients (47%) in the 6 to 14 years age group had a BMI in the overweight or obese range.

**Clinical Presentation**

Fifty percent of the patients had a known sick contact with confirmed or suspected COVID-19. Forty-five percent of all patients...
had at least 1 comorbidity at initial presentation, with obesity, asthma, and malignancy as the most common pre-existing conditions (Table 1). Fever (80%) was the most common presenting symptom, followed by cough (39%) and shortness of breath or dyspnea (29%) (Fig 1). Overall, older children had similar symptomatology to those described in adult patients with COVID-19.20 There were 9 patients (11%) with acute appendicitis (7 were aged 6–14 years and 2 were aged 15–21 years; 3 patients had perforated appendix) and 2 children (2%) with intussusception.

**Laboratory Characteristics at Initial Presentation**

Leukopenia and lymphopenia were observed in 22% and 36% of the patients, respectively. C-reactive protein (CRP) was elevated in 67% (n = 54) of patients, and procalcitonin was elevated in 34% (n = 35) of patients. Other inflammatory markers, such as interleukin-6 (IL-6), D-dimer, and lactate dehydrogenase, were elevated in two-thirds and ferritin was increased in one-third of the patients (Table 2).

**Chest Radiographic Imaging**

Forty-eight (59%) patients had chest radiographs performed, of which 42 (88%) were abnormal. Chest radiographic findings included bilateral ground glass or hazy

---

**TABLE 1** Baseline Characteristics of all Hospitalized Pediatric and Adolescent Patients With SARS-CoV-2 and Comparison Between Those Admitted to Acute or Critical Care Units

<table>
<thead>
<tr>
<th></th>
<th>All Patients (n = 82)</th>
<th>Acute Care Admission (n = 58)</th>
<th>Critical Care Admission (n = 23)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR)</td>
<td>5 y (2.5 mo–15.2 y)</td>
<td>6.7 mo (1 mo–11.5 y)</td>
<td>10 y (2.7 mo–18 y)</td>
<td>.16</td>
</tr>
<tr>
<td>Sick contacts, n (%)</td>
<td>45 (55)</td>
<td>27 (45)</td>
<td>18 (78)</td>
<td>.008</td>
</tr>
<tr>
<td>Comorbidities, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any comorbidity</td>
<td>38 (46)</td>
<td>22 (37)</td>
<td>16 (70)</td>
<td>.008</td>
</tr>
<tr>
<td>Asthma</td>
<td>12 (15)</td>
<td>7 (12)</td>
<td>5 (22)</td>
<td>.26</td>
</tr>
<tr>
<td>Obesitya</td>
<td>19 (40)</td>
<td>9 (28)</td>
<td>10 (63)</td>
<td>.02</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>4 (5)</td>
<td>1 (2)</td>
<td>3 (13)</td>
<td>.06</td>
</tr>
<tr>
<td>Congenital heart disease</td>
<td>1 (1)</td>
<td>0</td>
<td>1 (4)</td>
<td>.28</td>
</tr>
<tr>
<td>Diabetes mellitus (type 1 or 2)</td>
<td>1 (1)</td>
<td>0</td>
<td>1 (4)</td>
<td>.28</td>
</tr>
<tr>
<td>Malignancy and/or immunosuppression</td>
<td>9 (11)</td>
<td>4 (7)</td>
<td>5 (22)</td>
<td>.10</td>
</tr>
<tr>
<td>Other</td>
<td>15 (16)</td>
<td>7 (12)</td>
<td>6 (26)</td>
<td>.11</td>
</tr>
</tbody>
</table>

*a Denominator for obesity includes patients ≥2 y age, 32 in acute care vs 16 in critical care.

---

**FIGURE 1** Presenting symptoms for all patients and their age wise distribution. (The percentages of symptoms in an age group for indicated symptom are on the y-axis, individual symptoms are on the x-axis, and the colors represent various age groups as shown in the figure).
FIGURE 2 Distribution of pediatric and adolescent patients in various age groups, need for admission to acute versus critical care units, and type of respiratory support required. (The numbers of patients are on the y-axis, individual bars represent various age groups, and different shades represent support required as shown in the figure.)

opacities in 20 (42%) patients, focal consolidation in 6 (13%), small airway inflammation in 15 (31%), pleural effusion in 3 (6%), and pneumothorax in 1 (1%) patient. Five children (6%) had computerized tomography of the chest, and 4 of them had bilateral ground glass or patchy airway opacities in the lungs.

Coinfections
Twelve patients (15%) in this cohort had coinfections. Sterile site culture results were negative, with the exception of 2 positive blood culture results (Klebsiella pneumoniae in a patient requiring mechanical ventilation and ECMO support; Klebsiella oxytoca and Streptococcus constellatus in a patient with a perforated appendix) and 2 positive urine cultures (Pseudomonas aeruginosa in patient with history of posterior urethral valve and Hutch diverticulum; and Candida dubliensis in a patient with diabetic ketoacidosis). Three patients had viral coinfections (rhinoenterovirus, respiratory syncytial virus, and influenza B).

Therapies Used for COVID-19
Hydroxychloroquine (alone or in combination with other therapies) was administered to 26% of patients, predominately early in the reporting period. Other therapies included tocilizumab (10%), remdesivir (6%), lopinavir plus ritonavir (2%), and convalescent plasma (1%). Patients with respiratory symptoms or with comorbidities were more likely to receive medications for the treatment of COVID-19. In total, 76% patients requiring respiratory support received therapies for COVID-19, compared with 6% of those who did not require any respiratory support (P < .001). Similarly, higher proportions of patients with any comorbidity received medications for COVID-19 than those who had no comorbidities (53% vs 11%, P < .001).

Respiratory Support
Twenty-nine patients (35%) required some form of respiratory support, of which 7 patients (9%) needed mechanical ventilation. The noninvasive ventilation modalities (maximum respiratory support required) included 12 patients (15%) on nasal cannula, 9 (11%) on high-flow nasal cannula, and 1 (1%) on bilevel positive airway pressure support. We performed a subanalysis and comparison between children who required any form of respiratory support and those who required no respiratory support during hospitalization. Patients who required respiratory support were older (median age: 17.1 years IQR: 8.1–18.8 years) vs 9 months (IQR: 5 months–10.2 years), P < .001 and more frequently had pre-existing comorbidities (69% vs 32%, P = .001). Children with obesity had increased need for respiratory support, but this was not statistically significant (41% vs 30%, P = .21). Children with a history of asthma were more likely to require respiratory support during hospitalization (28% vs 8%, P = .02).

Critical Care Versus Acute Care Admission
Children with any pre-existing comorbidity were more likely to require critical care than acute care during hospitalization (70% vs 37%, P = .008). Obesity is the most common risk factor associated with the need for critical care (63% vs 28%, P = .02). There was no difference in the proportions of overweight children (≥2 years) admitted to acute or critical care (25% vs 13%, P = .41). Children admitted to critical care were more likely to have sick contacts than those admitted to acute care units (78% vs 45%, P = .008). In addition, they were more likely to have elevated CRP, IL-6, and alanine aminotransferase (Table 2). Children admitted to critical care had higher rates of renal dysfunction at presentation than those admitted to acute care with elevated creatinine levels for age (43% vs 10%, P = .002) and low estimated glomerular filtration rate (56% vs 19%, P = .01). Initial vital signs were not significantly different between 2 groups. The median length of stay was higher among patients needing critical care (8 days [IQR: 4–24] vs 2 days [IQR: 2–4], P < .001).

DISCUSSION
In this study, we describe the largest pediatric case series to date in the United States of hospitalized children with SARS-CoV-2. In contrast to previously published pediatric SARS-CoV-2 inpatient cohorts, in which the final clinical outcome of many patients (up to one-third) had not yet been determined at the time of publication, we capture clinical outcomes through hospital discharge for all patients.13–14 We compared these patients on the basis of their level of care and age groups. Additionally, we described a more-granular comparison between children who required respiratory support to those with no respiratory support than previously described in the literature.

Categorization of the disease severity among children with SARS-CoV-2 has been variable among limited published data11–15 with the main focus being patients requiring mechanical ventilation (Supplemental Table 3). Noninvasive respiratory support poses a significant morbidity burden for both patients and health care systems. The guidance regarding performing early intubation or trying noninvasive ventilation...
TABLE 2 Laboratory and Microbiologic Indices Among Pediatric and Adolescent Patients With SARS-CoV-2 and Comparison Between Those Admitted to Acute or Critical Care Units

<table>
<thead>
<tr>
<th>Laboratory Indices^</th>
<th>Available Data, n</th>
<th>All (n = 82)</th>
<th>Acute Care (n = 59)</th>
<th>Critical Care (n = 23)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin, c &lt;10 mg/dL</td>
<td>78</td>
<td>11/78 (14)</td>
<td>7/56 (13)</td>
<td>4/22 (18)</td>
<td>.49</td>
</tr>
<tr>
<td>Platelets, c 150 – 10^3/μL</td>
<td>76</td>
<td>11/76 (15)</td>
<td>6/54 (11)</td>
<td>5/22 (23)</td>
<td>.19</td>
</tr>
<tr>
<td>White blood cells count</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5 × 10^3/μL</td>
<td>78</td>
<td>17/78 (22)</td>
<td>14/56 (25)</td>
<td>3/22 (14)</td>
<td>.37</td>
</tr>
<tr>
<td>&gt;11 × 10^3/μL</td>
<td>65a</td>
<td>21/65 (32)</td>
<td>12/45 (27)</td>
<td>9/20 (45)</td>
<td>.15</td>
</tr>
<tr>
<td>&gt;30 × 10^3/μL for newborns &lt;28 d of life</td>
<td>13</td>
<td>0/13</td>
<td>0/11</td>
<td>0/2</td>
<td>—</td>
</tr>
<tr>
<td>Absolute lymphocyte count, &lt;1500 cells/μL</td>
<td>77</td>
<td>28/77 (36)</td>
<td>18/56 (32)</td>
<td>10/21 (48)</td>
<td>.21</td>
</tr>
<tr>
<td>Absolute neutrophils count, &gt;1500 cells/μL</td>
<td>78</td>
<td>10/78 (13)</td>
<td>9/56 (16)</td>
<td>1/22 (5)</td>
<td>.27</td>
</tr>
<tr>
<td>CRP, &gt;10 mg/dL</td>
<td>54</td>
<td>36/54 (67)</td>
<td>18/54 (53)</td>
<td>18/20 (80)</td>
<td>.005</td>
</tr>
<tr>
<td>Procalcitonin, ≥0.5 ng/mL</td>
<td>35</td>
<td>12/35 (34)</td>
<td>5/19 (26)</td>
<td>7/16 (44)</td>
<td>.41</td>
</tr>
<tr>
<td>IL-6, ≥5 pg/mL</td>
<td>29</td>
<td>20/29 (69)</td>
<td>10/18 (56)</td>
<td>10/11 (91)</td>
<td>.04</td>
</tr>
<tr>
<td>D-dimer, ≥250 ng/mL</td>
<td>23</td>
<td>15/23 (65)</td>
<td>9/14 (64)</td>
<td>6/9 (67)</td>
<td>.91</td>
</tr>
<tr>
<td>Ferritin, ≥250 ng/mL</td>
<td>21</td>
<td>8/21 (38)</td>
<td>4/11 (36)</td>
<td>4/10 (40)</td>
<td>.99</td>
</tr>
<tr>
<td>Lactate dehydrogenase, ≥250 IU/L</td>
<td>33</td>
<td>28/33 (85)</td>
<td>17/20 (85)</td>
<td>11/13 (85)</td>
<td>.97</td>
</tr>
<tr>
<td>Creatinine, elevated level for age^</td>
<td>69</td>
<td>14/69 (20)</td>
<td>5/48 (10)</td>
<td>9/21 (43)</td>
<td>.002</td>
</tr>
<tr>
<td>eGFR, &lt;90 mL/min/1.73 m^2</td>
<td>42</td>
<td>14/42 (33)</td>
<td>5/26 (19)</td>
<td>9/16 (56)</td>
<td>.01</td>
</tr>
<tr>
<td>Troponins, &gt;0.5 ng/dL</td>
<td>27</td>
<td>2/27 (7)</td>
<td>0/13 (0)</td>
<td>2/14 (14)</td>
<td>.48</td>
</tr>
<tr>
<td>Aspartate aminotransferase, &gt;40 U/L</td>
<td>61</td>
<td>29/61 (48)</td>
<td>16/41 (39)</td>
<td>13/20 (65)</td>
<td>.06</td>
</tr>
<tr>
<td>Alanine aminotransferase, &gt;40 U/L</td>
<td>62</td>
<td>13/62 (21)</td>
<td>4/42 (10)</td>
<td>9/20 (45)</td>
<td>.002</td>
</tr>
<tr>
<td>Microbiologic indices</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood culture positive</td>
<td>58</td>
<td>2/58 (3)</td>
<td>0/37 (0)</td>
<td>2/21 (10)</td>
<td>.13</td>
</tr>
<tr>
<td>Urine culture positive</td>
<td>34</td>
<td>2/34 (6)</td>
<td>1/21 (5)</td>
<td>1/13 (8)</td>
<td>.99</td>
</tr>
<tr>
<td>Cerebrospinal fluid culture positive</td>
<td>19</td>
<td>0/19</td>
<td>0/17</td>
<td>0/2</td>
<td>—</td>
</tr>
<tr>
<td>Respiratory viral panel positive^ (except SARS-CoV-2)</td>
<td>47</td>
<td>3/47 (6)</td>
<td>1/32 (3)</td>
<td>2/15 (13)</td>
<td>.24</td>
</tr>
<tr>
<td>Coinfection (bacterial or viral or fungal)</td>
<td>82</td>
<td>12/82 (15)</td>
<td>5/58 (8)</td>
<td>7/23 (30)</td>
<td>.01</td>
</tr>
</tbody>
</table>

^ eGFR, estimated glomerular filtration rate; —, not applicable.

^a All values expressed as n/number of patients with available data for a variable in that category (%).

^b Excluding infants <28 d of life.

^c Normal values range used for "creatinine for age" in mg/dL: newborn: 0.3–1.0, infant: 0.2–0.4, 1 to 9 y: 0.3–0.7, 10 to 17 y: 0.5–1.0, 18 to 21 y: 0.9–1.3 (male), 0.6–1.1 (female).

^d Denominator for eGFR includes patients ≥2 y age. eGFR calculated using the "bedside Schwartz equation" for patients aged 2 to 17 y and "Chronic Kidney Disease Epidemiology Collaboration creatinine equation" for patients aged 18–21 y.

^e BioFire FilmArray respiratory panel (bioMérieux).

modalities has rapidly evolved for patients with COVID-19 and worsening respiratory status. Therefore, in our study, we have looked at the data in a more comprehensive manner and compared children on the basis of their level of care to understand the burden of acute and critical care admissions in pediatric patients as well as elucidated the features of those children who required respiratory support (invasive or noninvasive). We recognize the need for standardizing descriptions of disease acuity and clinical course in the pediatric literature so we can arrive at a more meaningful understanding of the impact of SARS-CoV-2 infection in children. Children with comorbidities were noted to be at increased risk for critical care admission and need for respiratory support in this study. Obesity is an important risk factor for SARS-CoV-2 admission in patients <60 years of age and is associated with an increased need for mechanical ventilation in at least 1 pediatric study. We speculate that children with obesity may be at increased risk for more severe illness because of SARS-CoV-2, as demonstrated for other viral infections, such as influenza A, and among children requiring critical care during hospitalization. This may be related to an altered immune response, reduced baseline pulmonary function, and association of progression to an inflammatory syndrome as described with other comorbid conditions in patients with obesity. In previously published case series from the United States, children with asthma were not at increased risk for critical care admission, but morbidity such as need for respiratory support were not described among them. In our larger cohort, asthma as a comorbidity was significantly higher among children who required some form of respiratory support when compared with those who required no respiratory support, although there was no
statistically significant increase in the need for critical care admission. We suggest that pediatricians and other care providers consider all comorbidities, particularly obesity and asthma, as potential risk factors for severe illness while caring for children during this pandemic.

In the described cohort, patients aged 15 to 21 years were the most severely affected, with three-quarters of them requiring some form of respiratory support. Patients aged <1 and 1 to 5 years had relatively milder symptoms, and few of them required respiratory support. These findings are in contrast to a large retrospective pediatric study from China, in which the largest proportion of severe and critical cases were in children aged <1 and 1 to 5 years. One-third of those cases were not laboratory confirmed for SARS-CoV-2, and there was no standardized testing for other viral illnesses in the Chinese study. The reasons for differences observed in disease severity among various age groups, despite higher nasopharyngeal viral load observed among infants compared with older children, is yet to be determined. Some possible explanations could be from evolving immunologic response to the viral infections in early life and age-dependent differential expression of cell surface angiotensin-converting enzyme 2 receptors.

Children <1 year of age were the most-represented age group in this study, which is similar to or slightly higher than other smaller studies from NYC. In the beginning of pandemic spread in the United States, when data on children with COVID-19 from China suggested higher severity of infection among infants and younger children, it is possible that more infants with confirmed infection were admitted to ensure safety of these children. We did observe a decreasing trend of admitting infants from the emergency department over time during course of pandemic as our understanding of this infection in children increased.

The most-common presenting symptoms in this study were fever and/or dry cough. Several children had atypical nonrespiratory presenting symptoms, such as acute abdominal pain, new-onset seizure, and new-onset diabetes. Although some of these associations have been described in adult and pediatric literature, it is unclear whether SARS-CoV-2 was the causative agent or if it was coincidentally diagnosed. Children admitted to critical care were more likely to have sick contacts than those admitted to acute care units. It is possible that families of patients admitted to critical care units may have reflected more on sick contacts or other aspects related to history (recall bias) or the clinical teams obtaining detailed history. Inflammatory markers were elevated in many of our patients, but only a few were associated with the need for critical care (CRP and IL-6). These findings suggest a similar, but likely less-severe, inflammatory process to that described in adult studies. Renal dysfunction was observed more in patients requiring critical care, which has been previously described in pediatric patients with greater illness severity. None of the patients required renal replacement therapy. The reasons for higher rate of renal dysfunction could be multifactorial, including hyperinflammation, cytokine storm, and complement dysregulation associated with COVID-19.

In addition, kidneys have increased expression of angiotensin-converting enzyme 2 receptor, potentially leading to viral entry and injury to the cells. Among radiographic findings, a majority of the patients requiring respiratory support had bilateral ground glass or patchy opacities in lungs, whereas in a few cases these findings did not correlate with the level of clinical support required. Potential targeted therapies for COVID-19 have limited efficacy data among children. However, these treatments were given on the basis of individual patient clinical characteristics and in an effort to treat the most severely affected children.

Thirteen percent of patients in our described cohort were diagnosed with acute appendicitis or intussusception on presentation. This is a higher rate than previously published case series from NYC area. All of these patients had gastrointestinal symptoms (abdominal pain, vomiting, or diarrhea), three-quarters of them had fever, and one-quarter had respiratory symptoms. It is possible that children taken to operating theater were more likely to get tested as per local infection prevention measures and were coincidentally found positive for SARS-CoV-2 during high prevalence of infection in the region. Viral infections are known to cause lymphadenopathy and hyperplasia of other lymphatic tissues, such as Peyer’s patches in the intestines, which may serve as a lead point resulting in intussusception, and inflammation of lymphoid tissue around the appendix, resulting in acute appendicitis. This association of acute appendicitis and intussusception with SARS-CoV-2 infection needs further exploration, including analysis of pathologic changes in the surgically removed appendix.

Our study has several important limitations, including a small sample size, limited geographical range, and its observational nature. Because of rapidly evolving testing and management guidelines for suspected cases with SARS-CoV-2 at all study locations, there may have been some initial inconsistency in diagnosis and management over this study period. Also, some of the associations and risk factors observed in our relatively small study cohort need to be explored in detail on a larger data set. Nonetheless, our focus on hospitalized pediatric patients with SARS-CoV-2 in 4 NYC Metropolitan area hospitals with widespread community transmission provides important data for pediatric clinicians.

CONCLUSIONS
This described cohort is the largest case series to date of hospitalized children with confirmed SARS-CoV-2 managed from admission to discharge. We observed that children with comorbidities, particularly obesity and asthma, are at increased risk for critical care admission and/or the need for respiratory support. Children with renal dysfunction at presentation may be at greater risk for the need for critical care. Understanding risk factors associated with severity of illness among children requires further investigation on a larger data set.
Acknowledgments

We acknowledge the extraordinary work of all staff members who took care of these patients in the middle of this pandemic. We thank the patients and families of the children included in this study.

REFERENCES


25. Honce R, Schultz-Cherry S. Impact of obesity on influenza A virus pathogenesis, immune response,


Characteristics of Hospitalized Children With SARS-CoV-2 in the New York City Metropolitan Area
Hospital Pediatrics originally published online October 8, 2020; originally published online October 8, 2020;

Updated Information & Services
including high resolution figures, can be found at:
http://hosppeds.aappublications.org/content/early/2020/12/19/hpeds.2020-001917

Supplementary Material
Supplementary material can be found at:
http://hosppeds.aappublications.org/content/suppl/2020/12/18/hpeds.2020-001917.DCSupplemental

References
This article cites 40 articles, 6 of which you can access for free at:
http://hosppeds.aappublications.org/content/early/2020/12/19/hpeds.2020-001917#BIBL

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.hosppeds.aappublications.org/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
http://www.hosppeds.aappublications.org/site/misc/reprints.xhtml
Characteristics of Hospitalized Children With SARS-CoV-2 in the New York City Metropolitan Area


*Hospital Pediatrics* originally published online October 8, 2020; originally published online October 8, 2020;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://hosppeds.aappublications.org/content/early/2020/12/19/hpeds.2020-001917

Data Supplement at:

http://hosppeds.aappublications.org/content/suppl/2020/12/18/hpeds.2020-001917.DCSupplemental